Drug Trial Radar · NCT07779252
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Apr 10, 2028
Study completion Apr 10, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either corabotase (the study drug) or placebo. There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of corabotase or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, and clinical evaluations. They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.
Conditions
- Moderate to Severe Glabellar Lines
Interventions
CorabotaseBiological
A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.
PlaceboBiological
A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants responding to treatmentTime frame: At Week 4
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Peking university first hospital
Beijing, China · Recruiting
Peking Union Medical College Hospital (PUMCH)
Beijing, China · Not yet recruiting
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
Xiangya School of Medicine at Central South University
Changsha, Hunan, China · Not yet recruiting
Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Not yet recruiting
Wuxi People's Hospital
Wuxi, Jiangsu, China · Recruiting
Huashan Hospital Affiliated to Fudan University
Jing’an, Shanghai Muncipality, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.